MedTrace Logo

Study to Determine the Safety, Tolerability, and Pharmacokinetic (PK) Profile of EGT0001474 in Healthy Volunteers

NCT00854113 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2019-06-06

Study results available
· View outcomes & findings →

Summary

This study evaluated the safety, tolerability and pharmacokinetics of single or multiple doses of EGT0001474.

Conditions

  • Safety and Tolerability of EGT0001474 in Healthy Volunteers

Interventions

DRUG

EGT0001474

Oral ascending doses given daily as capsules for up to 14 days

DRUG

Placebo

Placebo to match EGT0001474

Sponsors & Collaborators

  • Theracos

    lead INDUSTRY

Principal Investigators

  • Mason W. Freeman, M.D. · Massachusetts General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2009-07-31
Completion
2009-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00854113 on ClinicalTrials.gov